newsfilter
← Latest News
GlobeNewswire·

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal